OBI Received a Civil Complaint from Taiwan Shilin District Court
2017.Jul.12
Clarification on the news article by China Times
2017.Jun.29
Clarification on the news article by Commercial Times
2017.Jun.28
Important Resolutions of AGM 2017
2017.Jun.11
Supplemental information on the approved application of Phase III clinical trial of OBI-822, the novel breast cancer drug, in China, US, and the EU
2017.Jun.01
OBI Pharma Announces Acquisition of the Novel First-in-class Anti-Cancer Drug OBI-3424 from Threshold Pharmaceuticals to be Developed as Potential Anti-Cancer Therapy for Cancers with High AKR1C3
2017.Apr.26
Announcement of explanation on the first instance judgment of the civil action between the Company against "Next Magazine"
2017.Apr.17
Announcement of explanation on the Company's criminal lawsuit against Next Magazine
2017.Apr.06
OBI-833, the cancer therapeutic vaccine, has met the primary safety indicators in Phase I clinical trial for US and Taiwan
2017.Mar.09
The board of directors have resolved not to distribute dividends
